BioCollections Worldwide, Inc. (BCW) announced today that it is commercially offering Abbott Molecular HIV-1 RealTime for HIV-1 viral load testing. The test is available to physicians and pharmaceutical customers through it's Miami headquarters facility. The new HIV-1 RealTime PCR precisely measures the quantity of circulating HIV-1 virus in plasma of infected patients ("viral load"). It can detect the full range of HIV viral subtypes that scientists have identified to date, and which until recently were particular to specific geographic regions. While the majority of HIV-1 isolates reported in the western hemisphere, Europe, and Australia continue to belong to subtype B, and while non-B subtypes A, C, D and E continue to be prevalent in Africa and Southeast Asia, global travel is facilitating the broad distribution of all HIV-1 subtypes worldwide. "With reports of non-B subtypes increasing globally, the ability of a test to detect and quantify these diverse subtypes are crucial to quality HIV patient care, treatment decision-making and molecular diagnostic development," said Sixto Pacheco, CCRC, President & CEO at BioCollections Worldwide, Inc. "We are excited to offer this methodology to our customers. We feel that it will not only help in the treatment decisions for our participating physicians, but will also cut down on turn-around times in delivery of results to our diagnostic development customers."